Compare BZUN & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZUN | AGEN |
|---|---|---|
| Founded | 2007 | 1994 |
| Country | China | United States |
| Employees | 6762 | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.3M | 147.4M |
| IPO Year | N/A | 1999 |
| Metric | BZUN | AGEN |
|---|---|---|
| Price | $2.78 | $3.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 277.8K | ★ 591.3K |
| Earning Date | 05-20-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 1.02 |
| Revenue | N/A | ★ $42,877,086.00 |
| Revenue This Year | $7.89 | $107.63 |
| Revenue Next Year | $6.16 | N/A |
| P/E Ratio | ★ N/A | $2.82 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $2.07 | $2.71 |
| 52 Week High | $4.88 | $7.34 |
| Indicator | BZUN | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 54.99 | 44.19 |
| Support Level | $2.62 | $2.93 |
| Resistance Level | $2.82 | $3.15 |
| Average True Range (ATR) | 0.13 | 0.21 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 52.44 | 31.67 |
Baozun Inc is engaged to provide its customers with end-to-end e-commerce solutions including the sales of apparel, home and electronic products, online store design and setup, visual merchandising and marketing, online store operations, customer services, warehousing and order fulfillment, as well as the holistic brand management, including tactic positioning, branding and marketing, retail and e-commerce operations, supply chain and logistics, and technology empowerment. It has two operating segments: E-Commerce (encompassing BEC and BZI) and Brand Management (representing BBM). The company generates maximum of its revenue from E-Commerce (encompassing BEC and BZI) segment.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.